Current eye research · 2026
Efficacy and Safety of a Single Tearmaestro® Liquid Pulsation Treatment for Meibomian Gland Dysfunction-Related Dry Eye Disease: A Prospective Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yue Yiyun, Xu Yan, Yan Jing, Shang Zhenying, Li Fei, Li Qiwei, Huang Yue, Yang Ruibo, Liu Hui, Zhang Chen, Zhao Shaozhen
Аннотация
PURPOSE: To evaluate the efficacy and safety of a single Tearmaestro® liquid pulsation treatment for meibomian gland dysfunction (MGD)-related dry eye disease.
METHODS: In this prospective trial, 31 patients with MGD-related dry eye received a single 12-minute treatment. The primary outcome was the change in the Ocular Surface Disease Index (OSDI) score from baseline to the 1-month follow-up. Secondary outcomes included tear film break-up time (TBUT), corneal fluorescein staining (CFS), lipid layer thickness (LLT), meibomian gland secretion (MGS) and orifice (MQS) scores, Schirmer I test, tear meniscus height (TMH), and safety parameters. All measures were assessed at baseline, 7 days, 1 month, and 3 months.
RESULTS: The primary outcome, demonstrated a significant reduction at 1 month (p < 0.0001), with improvements sustained at all follow-ups (all p < 0.0001). Key secondary outcomes also showed significant improvement: TBUT increased at 1 and 3 months (p < 0.05), and CFS improved at 3 months (p < 0.0001). Significant enhancements in LLT, MQS, and MGS were observed at 1 and/or 3 months (all p < 0.01). LLT positively correlated with TBUT (p < 0.01) and negatively with CFS (p < 0.05). No serious adverse events occurred.
CONCLUSION: A single Tearmaestro® liquid pulsation treatment significantly improves the primary outcome of patient-reported symptoms at 1 month, with concurrent benefits in tear film stability and meibomian gland function lasting up to 3 months. The treatment demonstrated a favorable safety profile, offering an efficient clinical option for MGD-related dry eye.
METHODS: In this prospective trial, 31 patients with MGD-related dry eye received a single 12-minute treatment. The primary outcome was the change in the Ocular Surface Disease Index (OSDI) score from baseline to the 1-month follow-up. Secondary outcomes included tear film break-up time (TBUT), corneal fluorescein staining (CFS), lipid layer thickness (LLT), meibomian gland secretion (MGS) and orifice (MQS) scores, Schirmer I test, tear meniscus height (TMH), and safety parameters. All measures were assessed at baseline, 7 days, 1 month, and 3 months.
RESULTS: The primary outcome, demonstrated a significant reduction at 1 month (p < 0.0001), with improvements sustained at all follow-ups (all p < 0.0001). Key secondary outcomes also showed significant improvement: TBUT increased at 1 and 3 months (p < 0.05), and CFS improved at 3 months (p < 0.0001). Significant enhancements in LLT, MQS, and MGS were observed at 1 and/or 3 months (all p < 0.01). LLT positively correlated with TBUT (p < 0.01) and negatively with CFS (p < 0.05). No serious adverse events occurred.
CONCLUSION: A single Tearmaestro® liquid pulsation treatment significantly improves the primary outcome of patient-reported symptoms at 1 month, with concurrent benefits in tear film stability and meibomian gland function lasting up to 3 months. The treatment demonstrated a favorable safety profile, offering an efficient clinical option for MGD-related dry eye.